Scenario valuation
May 13, 2022
Scenario valuation of the shares in Auxesis Pharma Holding AB prior to the launch of the company’s analgesic product ASA.P is now available. One-Pager Scenario
Scenario valuation of the shares in Auxesis Pharma Holding AB prior to the launch of the company’s analgesic product ASA.P is now available. One-Pager Scenario
The shareholders in 559195-6486 Auxesis Pharma Holding AB, is hereby convened to the Annual General Meeting on June 10, 2022 at 15.00 in the conference
Welcome as Board Members – Charlotta Larsson and Rune Nordström. Thank you to all shareholders for a great meeting and big thanks to Lars Larsson
Auxesis Pharma Holding AB has signed a license agreement with Pharma America Corp. in Florida, for a powerful introduction to the entire Americas. The ASA.P®
En beviljad SME status från EMA betyder att bolaget får lättare tillgång till regulatorisk, finansiell och administrativ assistans från EMA inom utveckling av företagets produkter
+46 (0) 736 27 15 65
Copyright All rights reserved AUXESIS PHARMA HOLDING AB 2021